Azitra (AZTR) Non Operating Income (2022 - 2026)
Azitra's (AZTR) quarterly Non Operating Income came in at $6684.0 in Q1 2026, down 79.04% YoY from $31893.0 in Q1 2025, and up 375.39% on a QoQ basis from $1406.0 in Q4 2025.
Azitra (AZTR) Non Operating Income (2022 - 2026) Analysis & Trends
Azitra (AZTR) has 5 years of Non Operating Income data on file, last reported at $6684.0 in Q1 2026.
- Quarterly Non Operating Income fell 79.04% year-over-year to $6684.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5595.0 (down 100.28% YoY) and the FY2025 annual result came in at $19614.0, down 99.03% from the prior year.
- Non Operating Income grew to $6684.0 in Q1 2026, from $1406.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $1.9 million in Q3 2024 to a low of -$3.0 million in Q2 2023.
- A 5-year average of -$210573.7 and a median of $6684.0 in 2026 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2024 — Non Operating Income soared 3705.71% — and 2025, when it sank 162.36%.
- Tracing AZTR's Non Operating Income over 5 years: stood at -$1.3 million in 2022, then jumped by 101.8% to $24285.0 in 2023, then soared by 106.11% to $50054.0 in 2024, then sank by 97.19% to $1406.0 in 2025, then jumped by 375.39% to $6684.0 in 2026.
- The last three Non Operating Income figures came in at $6684.0 (Q1 2026), $1406.0 (Q4 2025), and $3956.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Azitra | 2.53 Mn | 2.53 Mn | - | 71,508.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 71,508.00 |
| Mar 31, 2026 | 6,684.00 |
| Dec 31, 2025 | 1,406.00 |
| Sep 30, 2025 | 3,956.00 |
| Jun 30, 2025 | -17,641.00 |
| Mar 31, 2025 | 31,893.00 |
| Dec 31, 2024 | 50,054.00 |
| Sep 30, 2024 | 1.92 Mn |
| Jun 30, 2024 | 28,287.00 |
| Mar 31, 2024 | 28,622.00 |
| Dec 31, 2023 | 24,285.00 |
| Sep 30, 2023 | 50,443.00 |
| Jun 30, 2023 | -3.00 Mn |
| Mar 31, 2023 | -888,718.00 |
| Dec 31, 2022 | -1.35 Mn |
| Sep 30, 2022 | -47,170.00 |